Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Mayer

Showing results (661-670 of 703) with videos related to

Pageof 71
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2020
TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline <i>BRCA</i> Carriers With HER2-Negative Breast Cancer (the INFORM trial)Nadine Tung, Banu Arun, Michele R Hacker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 12, 2019
TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR<sup>+</sup> Metastatic Triple-Negative Breast CancerBrian D Lehmann, Vandana G Abramson, Melinda E Sanders, et al.
Frontiers in Molecular Biosciences|July 30, 2021
Small Molecule Microcrystal Electron Diffraction for the Pharmaceutical Industry-Lessons Learned From Examining Over Fifty SamplesJessica F Bruhn, Giovanna Scapin, Anchi Cheng, et al.
ESMO Open|March 11, 2026
TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancerS Jacob, E L Mayer, N Kacik, et al.
The Journal of Experimental Medicine|March 20, 2023
Single-cell profiling identifies a novel human polyclonal unconventional T cell lineageLore Billiet, Laurenz De Cock, Guillem Sanchez Sanchez, et al.
Nature|March 4, 2026
A glucocorticoid-FAS axis controls immune evasion during metastatic seedingMonica Cassandras, Xavier Sanchez, Lauren Hsu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2025
Circulating tumor cells dynamics after CDK4/6 inhibitor for hormone-receptor positive metastatic breast cancer: a biomarker analysis from the PACE phase II studyLorenzo Gerratana, Carolina Reduzzi, Yue Ren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2015
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast CancerSteven J Isakoff, Erica L Mayer, Lei He, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 15, 2013
Functional genetic variation in NFKBIA and susceptibility to childhood asthma, bronchiolitis, and bronchopulmonary dysplasiaSalman Ali, Aaron F Hirschfeld, Matthew L Mayer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2012
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancerLisa A Carey, Hope S Rugo, P Kelly Marcom, et al.
Pageof 71

Showing results (661-670 of 703) with videos related to

Sort By:
Pageof 71
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2020
TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline <i>BRCA</i> Carriers With HER2-Negative Breast Cancer (the INFORM trial)Nadine Tung, Banu Arun, Michele R Hacker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 12, 2019
TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR<sup>+</sup> Metastatic Triple-Negative Breast CancerBrian D Lehmann, Vandana G Abramson, Melinda E Sanders, et al.
Frontiers in Molecular Biosciences|July 30, 2021
Small Molecule Microcrystal Electron Diffraction for the Pharmaceutical Industry-Lessons Learned From Examining Over Fifty SamplesJessica F Bruhn, Giovanna Scapin, Anchi Cheng, et al.
ESMO Open|March 11, 2026
TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancerS Jacob, E L Mayer, N Kacik, et al.
The Journal of Experimental Medicine|March 20, 2023
Single-cell profiling identifies a novel human polyclonal unconventional T cell lineageLore Billiet, Laurenz De Cock, Guillem Sanchez Sanchez, et al.
Nature|March 4, 2026
A glucocorticoid-FAS axis controls immune evasion during metastatic seedingMonica Cassandras, Xavier Sanchez, Lauren Hsu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2025
Circulating tumor cells dynamics after CDK4/6 inhibitor for hormone-receptor positive metastatic breast cancer: a biomarker analysis from the PACE phase II studyLorenzo Gerratana, Carolina Reduzzi, Yue Ren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2015
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast CancerSteven J Isakoff, Erica L Mayer, Lei He, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 15, 2013
Functional genetic variation in NFKBIA and susceptibility to childhood asthma, bronchiolitis, and bronchopulmonary dysplasiaSalman Ali, Aaron F Hirschfeld, Matthew L Mayer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2012
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancerLisa A Carey, Hope S Rugo, P Kelly Marcom, et al.
Pageof 71